{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:31:51Z","timestamp":1793223111635,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001588","name":"Enterprise Ireland","doi-asserted-by":"publisher","award":["Disruptive Technologies Innovation Fund (DTIF)"],"award-info":[{"award-number":["Disruptive Technologies Innovation Fund (DTIF)"]}],"id":[{"id":"10.13039\/501100001588","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Dublin, Trinity College"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40273-024-01413-8","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T18:02:31Z","timestamp":1722016951000},"page":"1091-1110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0148-7805","authenticated-orcid":false,"given":"Shikha","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McConnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve","family":"Lowery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacintha","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"McCullagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the HEALED Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"issue":"1","key":"1413_CR1","first-page":"26","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26\u201338.","journal-title":"Prz Gastroenterol."},{"issue":"10251","key":"1413_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635\u201348.","journal-title":"Lancet"},{"key":"1413_CR3","unstructured":"National Cancer Institute. Stomach cancer survival rates and prognosis. United States 2023. https:\/\/www.cancer.gov\/types\/stomach\/survival#:~:text=Stomach%20Cancer%20Statistics&text=The%205%2Dyear%20relative%20survival%20rates%20for%20different%20stages%20of,nearby%20lymph%20nodes%20or%20organs. Accessed 21 Apr 2023."},{"issue":"10","key":"1413_CR4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2022;33(10):1005\u201320.","journal-title":"Ann Oncol"},{"key":"1413_CR5","unstructured":"U.S. Food & drug administration. FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer?utm_medium=email&utm_source=govdelivery. Accessed 27 Apr 2023."},{"issue":"10418","key":"1413_CR6","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197\u2013208.","journal-title":"Lancet"},{"issue":"11","key":"1413_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh D-Y, Ya\u00f1ez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"issue":"35","key":"1413_CR8","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31(35):4438\u201344.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1413_CR9","first-page":"CD004064","volume":"8","author":"AD Wagner","year":"2017","unstructured":"Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):CD004064.","journal-title":"Cochrane Database Syst Rev"},{"key":"1413_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.12703\/r\/12-2","volume":"12","author":"JE Rogers","year":"2023","unstructured":"Rogers JE, Ajani JA. Recent advances in the management of gastric adenocarcinoma patients. Fac Rev. 2023;12:2.","journal-title":"Fac Rev."},{"issue":"2","key":"1413_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"25","key":"1413_CR12","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330.","journal-title":"N Engl J Med"},{"key":"1413_CR13","unstructured":"Astellas. U.S. FDA acknowledges Astellas' resubmission of biologics license application for Zolbetuximab and sets new action date. [Press release]. https:\/\/www.astellas.com\/en\/news\/29186. Accessed 31 May 2024."},{"issue":"11","key":"1413_CR14","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","volume":"23","author":"ZA Wainberg","year":"2022","unstructured":"Wainberg ZA, Enzinger PC, Kang Y-K, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): A randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022;23(11):1430\u201340.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1413_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/1940-6207.CAPR-19-0372","volume":"13","author":"L Ji","year":"2020","unstructured":"Ji L, Liu Z, Zhou B, Cai Y, An F, Wang L, et al. Community-based pilot study of a screening program for gastric cancer in a Chinese population. Cancer Prev Res (Phila). 2020;13(1):73\u201382.","journal-title":"Cancer Prev Res (Phila)"},{"key":"1413_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3389\/fphar.2018.00404","volume":"9","author":"V Kumar","year":"2018","unstructured":"Kumar V, Soni P, Garg M, Kamholz S, Chandra AB. Emerging therapies in the management of advanced-stage gastric cancer. Front Pharmacol. 2018;9:404.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1413_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/annonc\/mdl501","volume":"18","author":"J Lee","year":"2007","unstructured":"Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007;18(5):886\u201391.","journal-title":"Ann Oncol"},{"issue":"7","key":"1413_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235848","volume":"15","author":"A Cotes Sanch\u00eds","year":"2020","unstructured":"Cotes Sanch\u00eds A, Gallego J, Hernandez R, Arrazubi V, Custodio A, Cano JM, et al. Second-line treatment in advanced gastric cancer: data from the Spanish AGAMENON registry. PLoS\u00a0One. 2020;15(7): e0235848.","journal-title":"PLoS\u00a0One"},{"issue":"2","key":"1413_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s13193-022-01695-4","volume":"14","author":"S Yildirim","year":"2023","unstructured":"Yildirim S, \u00d6zveren A. Second-line chemotherapy in gastric cancer: a retrospective study. Indian J Surg Oncol. 2023;14(2):423\u20137.","journal-title":"Indian J Surg Oncol"},{"issue":"6","key":"1413_CR20","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1111\/bcp.14275","volume":"87","author":"H Lloyd-Williams","year":"2021","unstructured":"Lloyd-Williams H, Hughes DA. A systematic review of economic evaluations of advanced therapy medicinal products. Br J Clin Pharmacol. 2021;87(6):2428\u201343.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"1413_CR21","doi-asserted-by":"publisher","first-page":"e1704","DOI":"10.1002\/onco.13907","volume":"26","author":"DV Catenacci","year":"2021","unstructured":"Catenacci DV, Chao J, Muro K, Al-Batran SE, Klempner SJ, Wainberg ZA, et al. Toward a treatment sequencing strategy: a systematic review of treatment regimens in advanced gastric cancer\/gastroesophageal junction adenocarcinoma. Oncologist. 2021;26(10):e1704\u201329.","journal-title":"Oncologist"},{"key":"1413_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.734323","volume":"11","author":"M Huang","year":"2021","unstructured":"Huang M, Li J, Yu X, Xu Q, Zhang X, Dai X, et al. Comparison of efficacy and safety of third-line treatments for advanced gastric cancer: a systematic review with bayesian network meta-analysis. Front Oncol. 2021;11: 734323.","journal-title":"Front Oncol"},{"issue":"24","key":"1413_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006884","volume":"96","author":"Y Zheng","year":"2017","unstructured":"Zheng Y, Zhu XQ, Ren XG. Third-line chemotherapy in advanced gastric cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(24): e6884.","journal-title":"Medicine (Baltimore)"},{"key":"1413_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103505","volume":"167","author":"JH Kim","year":"2021","unstructured":"Kim JH, Zang DY, Jang HJ, Kim HS. A Bayesian network meta-analysis on systemic therapy for previously treated gastric cancer. Crit Rev Oncol Hematol. 2021;167: 103505.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"1413_CR25","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s12029-023-00932-5","volume":"54","author":"LA Abderhalden","year":"2023","unstructured":"Abderhalden LA, Wu P, Amonkar MM, Lang BM, Shah S, Jin F, et al. Clinical outcomes for previously treated patients with advanced gastric or gastroesophageal junction cancer: a systematic literature review and meta-analysis. J Gastrointest Cancer. 2023;54(4):1031\u201345.","journal-title":"J Gastrointest Cancer"},{"key":"1413_CR26","unstructured":"Sharma S, Carey N, McConnell D, McCullagh L. Systematic Review of economic evaluations of systemic treatments for advanced and metastatic gastric cancer. PROSPERO CRD42023405951 2023. [Protocol]. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42023405951. Accessed 19 Jan 2023."},{"issue":"4","key":"1413_CR27","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group* P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1413_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jval.2021.01.002","volume":"24","author":"OL Mandrik","year":"2021","unstructured":"Mandrik OL, Severens JH, Bardach A, et al. Critical appraisal of systematic reviews with costs and cost-effectiveness outcomes: an ISPOR good practices task force report. Value Health. 2021;24(4):463\u201372.","journal-title":"Value Health"},{"key":"1413_CR29","unstructured":"Health Information and Quality Authority (HIQA). Guidelines for the Retrieval and Interpretation of Economic Evaluations of Health Technologies in Ireland Ireland. 2014. https:\/\/www.hiqa.ie\/sites\/default\/files\/2017-01\/Guidelines-Retrieval-and-Interpretation-of-Econ-Lit.pdf. Accessed 14 Apr 2023."},{"issue":"6","key":"1413_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/emermed-2020-209567","volume":"37","author":"M Amir-Behghadami","year":"2020","unstructured":"Amir-Behghadami M, Janati A. Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020;37(6):387.","journal-title":"Emerg Med J"},{"key":"1413_CR31","doi-asserted-by":"publisher","first-page":"175883591987772","DOI":"10.1177\/1758835919877726","volume":"11","author":"J Cheng","year":"2019","unstructured":"Cheng J, Cai M, Shuai X, et al. First-line systemic therapy for advanced gastric cancer: a systematic review and network meta-analysis. Ther Adv Med Oncol. 2019;11:1758835919877726.","journal-title":"Ther Adv Med Oncol"},{"key":"1413_CR32","unstructured":"Scottish Intercollegiate Guidelines Network. Search filters economic studies. Edinburgh. 2022."},{"issue":"1","key":"1413_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jval.2019.07.003","volume":"23","author":"C Gorry","year":"2020","unstructured":"Gorry C, McCullagh L, Barry M. Economic evaluation of systemic treatments for advanced melanoma: a systematic review. Value Health. 2020;23(1):52\u201360.","journal-title":"Value Health."},{"issue":"6","key":"1413_CR34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40273-021-01112-8","volume":"40","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics. 2022;40(6):601\u20139.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1413_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","volume":"24","author":"Z Philips","year":"2006","unstructured":"Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355\u201371.","journal-title":"Pharmacoeconomics"},{"key":"1413_CR36","unstructured":"Organisation for Economic Co-operation and Development. Purchasing power parities (PPP). 2023. https:\/\/data.oecd.org\/conversion\/purchasing-power-parities-ppp.htm. Accessed 06 July 2023."},{"key":"1413_CR37","unstructured":"Canada Drug and Health Technology Agency (CADTH). pan-Canadian Oncology Drug Review Final Economic Guidance Report: Trifluridine-Tipiracil (Lonsurf) for Gastric Cancer. 2020. https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10197TrifluridineTipiracilGC_inEGR_NOREDACT-ABBREV_EC24Mar2020_final.pdf. Accessed 16 May 2023."},{"issue":"11","key":"1413_CR38","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M, et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437\u201348.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1413_CR39","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12094-019-02127-6","volume":"22","author":"K Zhou","year":"2020","unstructured":"Zhou K, Zhou J, Zhang M, Liao W, Li Q. Cost-effectiveness of trifluridine\/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer. Clin Transl Oncol. 2020;22(3):337\u201343.","journal-title":"Clin Transl Oncol"},{"key":"1413_CR40","unstructured":"Scottish Medicines Consortium. SMC2329: trifluridine\/tipiracil 15mg\/6.14mg and 20mg\/8.19mg film-coated tablets (Lonsurf\u00ae) 2021. [Medicines advice]. https:\/\/www.scottishmedicines.org.uk\/media\/6026\/trifluridinetipiracil-lonsurf-final-may-2021-for-website.pdf. Accessed 17 May 2023."},{"key":"1413_CR41","unstructured":"National Institute for Health and Care Excellence (NICE). Trifluridine\u2013tipiracil for treating metastatic gastric cancer or gastrooesophageal junction adenocarcinoma after 2 or more treatments (TA852) 2022. [Technology appraisal guidance]. www.nice.org.uk\/guidance\/ta852. Accessed 18 May 2023."},{"issue":"2","key":"1413_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14737167.2021.1921576","volume":"22","author":"G Gourzoulidis","year":"2022","unstructured":"Gourzoulidis G, Koulentaki M, Koumarianou A, et al. Cost-effectiveness of trifluridine\/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece. Expert Rev Pharmacoecon Outcomes Res. 2022;22(2):259\u201369.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1413_CR43","unstructured":"National Institute for Health and Care Excellence (NICE). Ramucirumab for treating advanced gastric cancer or gastro\u2013oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378) 2016 [Technology appraisal guidance]. www.nice.org.uk\/guidance\/ta378. Accessed 24 May 2023."},{"key":"1413_CR44","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00280-012-2027-3","volume":"71","author":"SJ Sym","year":"2013","unstructured":"Sym SJ, Hong J, Park J, Cho EK, Lee JH, Park YH, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil\/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol. 2013;71:481\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1413_CR45","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","volume":"15","author":"HE Ford","year":"2014","unstructured":"Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15(1):78\u201386.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1413_CR46","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh S-C, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224\u201335.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1413_CR47","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/annonc\/mdt002","volume":"24","author":"A Roy","year":"2013","unstructured":"Roy A, Park S, Cunningham D, Kang Y-K, Chao Y, Chen L-T, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013;24(6):1567\u201373.","journal-title":"Ann Oncol"},{"issue":"15","key":"1413_CR48","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","volume":"47","author":"PC Thuss-Patience","year":"2011","unstructured":"Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2014a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(15):2306\u201314.","journal-title":"Eur J Cancer"},{"issue":"9911","key":"1413_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"C Fuchs","year":"2014","unstructured":"Fuchs C, Tomasek J, Yong C, Dumitru F, Passalacqua R, Goswami C, et al. REGARD Trial Investigators Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31\u20139.","journal-title":"Lancet"},{"issue":"1","key":"1413_CR50","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/phar.1870","volume":"37","author":"SW Lam","year":"2017","unstructured":"Lam SW, Wai M, Lau JE, et al. Cost-effectiveness analysis of second-line chemotherapy agents for advanced gastric cancer. Pharmacother J Hum Pharmacol Drug Ther. 2017;37(1):94\u2013103.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"12","key":"1413_CR51","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.clinthera.2017.10.017","volume":"39","author":"S Saito","year":"2017","unstructured":"Saito S, Muneoka Y, Ishikawa T, Akazawa K. Cost-effectiveness of paclitaxel + ramucirumab combination therapy for advanced gastric cancer progressing after first-line chemotherapy in japan. Clin Ther. 2017;39(12):2380\u20138.","journal-title":"Clin Ther"},{"issue":"9","key":"1413_CR52","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s12094-017-1647-9","volume":"19","author":"K Zhou","year":"2017","unstructured":"Zhou K, Wen F, Zhang P, et al. Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer. Clin Transl Oncol. 2017;19(9):1117\u201324.","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"1413_CR53","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/1078155217707335","volume":"24","author":"M Kimura","year":"2018","unstructured":"Kimura M, Usami E, Teramachi H, Yoshimura T. Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer. J Oncol Pharm Pract. 2018;24(6):403\u201311.","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"1413_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232240","volume":"15","author":"S Li","year":"2020","unstructured":"Li S, Peng L, Tan C, et al. Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. PLoS\u00a0One. 2020;15(5): e0232240.","journal-title":"PLoS\u00a0One"},{"key":"1413_CR55","doi-asserted-by":"publisher","first-page":"2198960","DOI":"10.1155\/2020\/2198960","volume":"2020","author":"B Lauren","year":"2020","unstructured":"Lauren B, Ostvar S, Silver E, et al. Cost-effectiveness analysis of biomarker-guided treatment for metastatic gastric cancer in the second-line setting. J Oncol. 2020;2020:2198960.","journal-title":"J Oncol"},{"key":"1413_CR56","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2017.35.15_suppl.4003","volume":"35","author":"CS Fuchs","year":"2017","unstructured":"Fuchs CS, Doi T, Jang RW-J, Muro K, Satoh T, Machado M, et al. KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. Am Soc Clin Oncol. 2017;35:4003.","journal-title":"Am Soc Clin Oncol"},{"issue":"10142","key":"1413_CR57","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang Y-J, Di Bartolomeo M, Mandal\u00e0 M, Ryu M-H, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123\u201333.","journal-title":"Lancet"},{"key":"1413_CR58","unstructured":"National Institute for Health and Care Excellence (NICE). Entrectinib for treating NTRK fusion-positive solid tumours (ID1512). 2020. [Technology appraisal guidance]. https:\/\/www.nice.org.uk\/guidance\/ta644. Accessed 01 June 2023."},{"key":"1413_CR59","doi-asserted-by":"publisher","first-page":"viii713","DOI":"10.1093\/annonc\/mdy424.017","volume":"29","author":"G Demetri","year":"2018","unstructured":"Demetri G, Paz-Ares L, Farago A, Liu S, Chawla S, Tosi D, et al. Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann Oncol. 2018;29:viii713.","journal-title":"Ann Oncol"},{"issue":"1","key":"1413_CR60","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3109\/0284186X.2011.594809","volume":"51","author":"B Hultman","year":"2012","unstructured":"Hultman B, Lundkvist J, Glimelius B, Nygren P, Mahteme H. Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from gastric cancer. Acta Oncol (Stockholm, Sweden). 2012;51(1):112\u201321.","journal-title":"Acta Oncol (Stockholm, Sweden)."},{"issue":"6","key":"1413_CR61","doi-asserted-by":"publisher","first-page":"zrab129","DOI":"10.1093\/bjsopen\/zrab129","volume":"5","author":"AG Powell","year":"2021","unstructured":"Powell AG, Wheat JR, Eley C, et al. Economic cost-utility analysis of stage-directed gastric cancer treatment. BJS Open. 2021;5(6):zrab129.","journal-title":"BJS Open"},{"issue":"1","key":"1413_CR62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320.","journal-title":"N Engl J Med"},{"key":"1413_CR63","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/1472-6963-13-283","volume":"13","author":"K Haga","year":"2013","unstructured":"Haga K, Matsumoto K, Kitazawa T, et al. Cost of illness of the stomach cancer in Japan\u2014a time trend and future projections. BMC Health Serv Res. 2013;13:283.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"1413_CR64","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5230\/jgc.2015.15.2.87","volume":"15","author":"S Karve","year":"2015","unstructured":"Karve S, Lorenzo M, Liepa AM, et al. Treatment patterns, costs, and survival among medicare-enrolled elderly patients diagnosed with advanced stage gastric cancer: analysis of a linked population-based cancer registry and administrative claims database. J Gastric Cancer. 2015;15(2):87\u2013104.","journal-title":"J Gastric Cancer"},{"issue":"2","key":"1413_CR65","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s41669-017-0043-2","volume":"2","author":"M Quintana","year":"2018","unstructured":"Quintana M, Toriz JA, Novick D, et al. Resources and costs associated with the treatment of advanced and metastatic gastric cancer in the Mexican public sector: a patient chart review. Pharmacoecon Open. 2018;2(2):191\u2013201.","journal-title":"Pharmacoecon Open"},{"issue":"9","key":"1413_CR66","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/13696998.2019.1617161","volume":"22","author":"D Novick","year":"2019","unstructured":"Novick D, Leonardi F, Lee Kay Pen D, et al. Retrospective analysis of patients with advanced or metastatic gastric cancer in Colombia. J Med Econ. 2019;22(9):891\u2013900.","journal-title":"J Med Econ"},{"key":"1413_CR67","unstructured":"Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. Report by the Decision Support Unit. 2011. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395885\/pdf\/Bookshelf_NBK395885.pdf. Accessed 03 Aug 2023."},{"issue":"3","key":"1413_CR68","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/1471-0528.17012","volume":"129","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BJOG. 2022;129(3):336\u201344.","journal-title":"BJOG"},{"issue":"8","key":"1413_CR69","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.jval.2012.07.008","volume":"15","author":"P Tappenden","year":"2012","unstructured":"Tappenden P, Chilcott J, Brennan A, Squires H, Stevenson M. Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework. Value Health. 2012;15(8):1127\u201336.","journal-title":"Value Health."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01413-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01413-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01413-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T09:54:58Z","timestamp":1726653298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01413-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":69,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1413"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01413-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"2 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article. Laura McCullagh is an Editorial Board Member of PharmacoEconomics. She was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Open Access funding provided by the IReL Consortium. This project is funded by Enterprise Ireland, through a Disruptive Technologies Innovation Fund (DTIF) Award (grant code: DT 2020 0265A).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors contributed to the study concept and design:\u00a0N.C., D.M., L.M., S.S., J.O., M.L. The first draft of the manuscript was written by S.S. and L.M., and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Conceptualisation: L.M., N.C., D.M., J.O. and M.L. Methodology: L.M., N.C., D.M. and S.S. Funding acquisition: J.O. and M.L. Supervision:\u00a0L.M., N.C. and D.M.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}